188 related articles for article (PubMed ID: 23458243)
1. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
3. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
5. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
[TBL] [Abstract][Full Text] [Related]
6. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
7. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
8. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
de Oliveira T; Engelbrecht S; Janse van Rensburg E; Gordon M; Bishop K; zur Megede J; Barnett SW; Cassol S
J Virol; 2003 Sep; 77(17):9422-30. PubMed ID: 12915557
[TBL] [Abstract][Full Text] [Related]
9. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
10. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
[TBL] [Abstract][Full Text] [Related]
11. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
12. Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.
Ojesina AI; Chaplin B; Sankalé JL; Murphy R; Idigbe E; Adewole I; Ekong E; Idoko J; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1167-74. PubMed ID: 18729771
[TBL] [Abstract][Full Text] [Related]
13. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
14. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
Kolli M; Lastere S; Schiffer CA
Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
[TBL] [Abstract][Full Text] [Related]
15. Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains.
Marlowe N; Flys T; Hackett J; Schumaker M; Jackson JB; Eshleman SH; ;
AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1119-25. PubMed ID: 15585104
[TBL] [Abstract][Full Text] [Related]
16. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.
Matsuoka-Aizawa S; Sato H; Hachiya A; Tsuchiya K; Takebe Y; Gatanaga H; Kimura S; Oka S
J Virol; 2003 Jan; 77(1):318-27. PubMed ID: 12477837
[TBL] [Abstract][Full Text] [Related]
17. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
19. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.
Cornelissen M; van den Burg R; Zorgdrager F; Lukashov V; Goudsmit J
J Virol; 1997 Sep; 71(9):6348-58. PubMed ID: 9261352
[TBL] [Abstract][Full Text] [Related]
20. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Lastere S; Dalban C; Collin G; Descamps D; Girard PM; Clavel F; Costagliola D; Brun-Vezinet F;
Antivir Ther; 2004 Apr; 9(2):221-7. PubMed ID: 15134184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
